Provention Bio, Inc. (PRVB)의 가격은 얼마입니까?

Provention Bio, Inc. (PRVB)의 가격은 $24.98입니다.

Provention Bio, Inc. (PRVB)의 시가 총액은 무엇입니까?

Provention Bio, Inc. (PRVB)의 시가 총액은 $1.01B입니다.

Provention Bio, Inc. (PRVB) PBR

Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.

연도	P/B 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/B 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/B 비율	P/B 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Moderna, Inc. MRNA.US	3.7087	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

P/B 비율

P/B 비율 차이

국가